Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Jun 21, 2014; 20(23): 7079-7088
Published online Jun 21, 2014. doi: 10.3748/wjg.v20.i23.7079
Published online Jun 21, 2014. doi: 10.3748/wjg.v20.i23.7079
First generation (wave 2) |
Simeprevir |
Faldaprevir |
Danoprevir |
Vaniprevir |
ABT-450/ABT-450r |
Asunaprevir |
Second generation |
MK-5172 |
ACH-2684 |
NS5A hepatitis C virus replication inhibitors |
Daclatasvir |
Ledipasvir |
ACH-3102 |
ABT-267 |
NS5B RNA dependent RNA polymerase inhibitors |
Sofosbuvir |
Mericitabine |
ABT-333 |
Host targeted agents |
Alisporivir |
Miravirsen |
Interferon-λ |
- Citation: Thompson JR. Emerging therapeutic options for the management of hepatitis C infection. World J Gastroenterol 2014; 20(23): 7079-7088
- URL: https://www.wjgnet.com/1007-9327/full/v20/i23/7079.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i23.7079